What is Pill Splitting?

Introduction

Pill-splitting refers to the practice of splitting a tablet or pill to provide a lower dose of the active ingredient, or to obtain multiple smaller doses, either to reduce cost or because the pills available provide a larger dose than required. Many pills that are suitable for splitting (aspirin tablets for instance) come pre-scored so that they may easily be halved.

It is unsafe to split some prescription medications.

Refer to Inverse Benefit Law.

Pill Splitters

A pill-splitter is a simple and inexpensive device to split medicinal pills or tablets, comprising some means of holding the tablet in place, a blade, and usually a compartment in which to store the unused part. The tablet is positioned, and the blade pressed down to split it. With care it is often possible to cut a tablet into quarters. Also available as consumer items are multiple pill splitters, which cut numerous round or oblong pills in one operation.

Pill Scoring

A drug manufacturer may score pills with a groove to both indicate that a pill may be split and to aid the practice of splitting pills. When manufacturers do create grooves in pills, the groove must be consistent for consumers to be able to use them effectively. Many manufacturers choose to not use grooves. The United States government Centre for Drug Evaluation and Research makes the following recommendations for manufacturers when scoring pills with grooves:

  1. Pills should only have grooves if the split dosage is at least the minimum therapeutic dosage of the medication.
  2. The split pill should not create a toxicity hazard.
  3. Drugs which should not be split should not be scored with a groove.
  4. The split pill should be stable for the expected temperature and humidity.
  5. The split pill should have an equivalent effect to a full pill at an equivalent dose.

Dosage Uniformity

In the US “uniformity of dosage units” is defined by the United States Pharmacopeia (USP), which describes itself as “the official public standards-setting authority for all prescription and over-the-counter medicines, dietary supplements, and other healthcare products manufactured and sold in the United States.” More than 140 countries develop or rely upon US pharmaceutical standards according to the USP.

The USP standard for dosage uniformity expresses statistical criteria in the complex language of sampling protocols. The pharmaceutical dosage literature sometimes boils this down as requiring a standard deviation in dosage weight of less than 6%, which roughly corresponds to the weaker rule-of-thumb offered for public consumption that the vast majority of dosage units should be within 15% of the dosage target. “Dosage unit” is a technical term which covers oral medications (tablets, pills, capsules), as well as non-oral delivery methods.

A 2002 study of pill-splitting as conducted in four American long-term care facilities determined that 15 of the 22 dispensed prescriptions evaluated (68%) had fragment weight variance in excess of USP standards.

Cost Savings

Pill-splitting can be used to save money on pharmaceutical costs, as many prescription pharmaceuticals are sold at prices less than proportional to the dose. For example, a 10 mg tablet of a drug might be sold for the same or nearly the same price as a 5 mg tablet. Splitting 10 mg tablets allows the patient to purchase half the number of tablets at a lower price than the same weight of 5 mg tablets.

Both specialist and generalist physicians are not sufficiently aware of and do not communicate with patients about the cost to them of medication.

Some Potentially Suitable Medications

Randall Stafford of the Stanford School of Medicine published a study in 2002 of common prescription medications in the United States in which he evaluates pill splitting for “potential cost savings and clinical appropriateness”. The study identifies eleven prescription medications that satisfied the study criteria, based on the American pharmaceutical cost structure, pill formulation, and dosages of the time. Most of the medications listed in the table from the psychiatric drug class are antidepressants.

Uniformity of Split

Not all tablets split equally well. In a 2002 study, Paxil, Zestril and Zoloft split cleanly with 0% rejects. Glucophage was described as a hard tablet, requiring significant force, causing tablet halves to fly. Glyburide exhibited very poor splitting with many splitting into multiple pieces. Hydrodiuril and Oretic crumbled. Lipitor did not split cleanly, and the coating peeled. The diamond shaped Viagra tablets made location of the midline difficult. The worst result reported was Oretic 25 mg in which 60% of tablets failed to split to within 15% of target weight.

Alternative Purpose

Some drugs have a few different uses, and are usually sold in different packages and different doses for different applications. The price for some applications may be very different from that for other purposes. One example is Minoxidil, which is well known as a hair-growth stimulant; the same drug under the name Loniten is used for blood pressure control in much larger doses at a much lower price per unit weight.

Risks

The US Food and Drug Administration (FDA) has called pill splitting “risky”. At the same time, the FDA approves the manufacture of pills which are intended to be split.

Splitting pills may result in uneven splitting and creating pieces which will not deliver accurate dosage. Pills which are split might not be correctly halved, making the cut pieces unequal in size. Some pills are difficult to split. Some pills (particularly some time release drugs) are unsafe to split, and there could be mistakes in identifying when pills should not be split.

Lawsuits

In a California court filing dated April 2001, Trial Lawyers for Public Justice (TLPJ) brought a class-action lawsuit against Kaiser Permanente (Timmis v. Kaiser Permanente) on the grounds that “Kaiser’s mandatory pill-splitting policy endangers patients’ health solely to enhance the HMO’s profits” in violation of the California Unfair Competition Law (UCL) and the California Consumer Legal Remedies Act (CLRA). In December 2004, the California Court of Appeal affirmed the trial court ruling that Kaiser’s policy did not violate UCL or CLRA, noting the suit had failed to present evidence that the policy was unsafe.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/Pill_splitting >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the British National Formulary for Children?

Introduction

The British National Formulary for Children (BNFC) is the standard UK paediatric reference for prescribing and pharmacology.

It contains a wide range of information and advice on prescribing for children – from newborn to adolescence. The entries are classified by group of drug, giving cautions for use, side effects, licensed use, indications and dose of most of the drugs available for children in the UK National Health Service. Though published in and for the United Kingdom, the vast bulk of the clinical information will apply in any country.

Authorship and Publication

The BNFC is jointly published annually by the British Medical Association, the Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health, and the Neonatal and Paediatric Pharmacists Group.

The principal contributors are acknowledged in the front pages.

It is overseen by the BNFC Paediatric Formulary Committee and edited by an international team of pharmacists.

Brief History

The BNFC developed from the British National Formulary (BNF), which prior to 2005 had provided information on the treatment of children, with the doses largely determined by calculations based on the body weight of the child. The guidance was provided by pharmacists and doctors whose expertise was in the care of adults.

This was an anomaly, as in relation to responses to medicines, the difference between a newborn and a sixteen year old is greater than the difference between a sixteen year old and a sixty year old.

Starting in 2002, Professor Martin Kendall, then chairman of the BNF Joint Formulary Committee worked to get things changed.

The UK Department of Health (now the DHSC) agreed to fund the BNFC, as it does the BNF, to ensure that NHS clinicians can have up to date information in their pockets.

The first edition was published in 2005, with George Rylance chairing the Paediatric Formulary Committee and Dinesh Mehta as the first executive editor. Anne, the Princess Royal attended the launch on 14 July.

Editions

The BNFC is published annually, but electronic updates are produced frequently, as needed.

Availability

Though not aimed at the general public, the BNFC, like the BNF is available for purchase. It is provided to NHS staff – usually through their employer, but may be obtained through Medicines Complete.

The app is available through the usual app stores.

For general advice on Medicines for Children the website of that name may be a better source of information than the BNFC. It is published by two of the publishers of the BNFC (RCPCH & NPPG) and the charity WellChild so can reasonably be judged to be authoritative (Though as the site notes, it is not a substitute for contact with an appropriate clinician or pharmacist).

Contents

Table of Contents

  • How BNF publications are constructed.
  • How to use BNF Publications in print.
  • Changes.
  • Guidance on Prescribing.
  • Prescription writing.
  • Supply of medicines.
  • Emergency supply of medicines.
  • Controlled drugs and drug dependence.
  • Adverse reactions to drugs.
  • Guidance on intravenous infusions.
  • Prescribing in hepatic impairment.
  • Prescribing in renal impairment.
  • Prescribing in pregnancy.
  • Prescribing in breast-feeding.
  • Prescribing in palliative care.
  • Drugs and sport.
  • Medicines optimisation.
  • Antimicrobial stewardship.
  • Prescribing in dental practice.

Notes on Drugs and Preparations

  • Gastro-intestinal system.
  • Cardiovascular system.
  • Respiratory system.
  • Nervous system.
  • Infection.
  • Endocrine system.
  • Genito-urinary system.
  • Immune system and malignant disease.
  • Blood and nutrition.
  • Musculoskeletal system.
  • Eye.
  • Ear, nose and oropharynx.
  • Skin.
  • Vaccines.
  • Anaesthesia.
  • Emergency treatment of poisoning.

Appendices and Indices

  • Interactions.
  • Borderline substances.
  • Cautionary and advisory labels for dispensed medicines.
  • Dental Practitioners’ Formulary.
  • Nurse Prescribers’ Formulary.
  • Non-medical prescribing.
  • Index of manufacturers.
  • Special-order Manufacturers.
  • Index.
  • Medical emergencies in the community.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/British_National_Formulary_for_Children >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the British National Formulary?

Introduction

The British National Formulary (BNF) is a United Kingdom (UK) pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about many medicines available on the UK National Health Service (NHS).

Information within the BNF includes indication(s), contraindications, side effects, doses, legal classification, names and prices of available proprietary and generic formulations, and any other notable points. Though it is a national formulary, it nevertheless also includes entries for some medicines which are not available under the NHS, and must be prescribed and/or purchased privately. A symbol clearly denotes such drugs in their entry.

It is used by pharmacists and doctors (both general practitioners (GPs) and specialist practitioners), and by other prescribing healthcare professionals (such as nurses, pharmacy technicians, paramedics, and dentists); as a reference for correct dosage, indication, interactions and side effects of drugs. It is also used as a reassurance by those administering drugs, for example a nurse on a hospital ward, and even for patients and others seeking an authoritative source of advice on any aspect of pharmacotherapy.

The British Pharmacopoeia (BP) specifies quality standards for the making of drugs listed in the BNF.

Development

Many individuals and organisations contribute towards the preparation of the BNF. It is jointly authored by the British Medical Association (BMA) and the Royal Pharmaceutical Society (RPS); and is jointly published by the BMJ Group (which is owned by the BMA), and the Pharmaceutical Press (owned by the RPS). It is published under the authority of a Joint Formulary Committee (JFC), which comprises representatives of the two professional bodies, and the Department of Health (DoH).

Information on drugs is drawn from the manufacturers’ product literature, medical and pharmaceutical literature, regulatory authorities and professional bodies. Advice is constructed from clinical literature, and reflects, as far as possible, an evaluation of the evidence from diverse sources. The BNF also takes account of authoritative national guidelines and emerging safety concerns. In addition, the Joint Formulary Committee takes advice on all therapeutic areas from expert clinicians; this ensures that the BNF’s recommendations are relevant to practice. However, in September 2013, the National Institute for Health and Care Excellence (NICE) in the UK opened a consultation on its draft decision not to give NICE accreditation to the processes to produce BNF publications following a review by an independent advisory committee.

Brief History

It was first published in 1949 as the National Formulary, with updated versions appearing every three years until 1976. The fifth version in 1957 saw its name change to The British National Formulary. A new look version, under the auspices of Owen Wade, was released in 1981. A study in Northern Ireland looking at prescribing in 1965, reported that the BNF was likely able to serve the requirements of prescribers in general practice, while also achieving a cost saving. By 2003, issue 46 of the BNF contained 3000 interactions or groups of interactions, with about 900 of these marked by a bullet.

Editions

A new edition of the BNF book is published twice-yearly; in March and September. As of March 2022, the current edition is 83, which was published in March 2022. It is a customary tradition that the colour of each new edition is radically different from the previous.

Availability

The BNF is presently available as a book, a website, and mobile applications – the latter for use on smartphones and tablets. The book is available for purchase, and the September edition is distributed to healthcare professionals in the UK at no direct cost to them. NHS workers and healthcare professionals in the HINARI group of developing nations are entitled to free access via MedicinesComplete following registration (requires provision of a name, an address, an email address, and a phone number). Other visitors can subscribe to the BNF on MedicinesComplete. Healthcare organisations can also subscribe to a customisable BNF via their corporate online intranet. In June 2012, the National Institute for Health and Care Excellence (NICE) released applications for offline access to the BNF on iOS and Android devices. An NHS Athens log-in is required to use this application, and monthly content updates are available, over an internet connection. NICE also provides a website providing the content of the BNF to the public, including non-NHS users.

Sister Publications

The British National Formulary for Children (BNFC) book, first published September 2005, is published yearly, and details the doses and uses of medicines in children from neonates to adolescents.

The Nurse Prescriber’s Formulary for Community Practitioners (NPF) is issued in print every two years (September, odd-numbered years), for use by District Nurses and Specialist Community Public Health Nurses (including Health Visitors) who have received training to become nurse prescribers.

BNF Sections

The British National Formulary is divided into various sections; with the main sections on drugs and preparations being organised by body system.

Table of Contents

  • Preface.
  • Acknowledgements.
  • How BNF publications are constructed.
  • How to use the BNF.
  • Changes.
  • Guidance on prescribing.
  • Prescription writing.
  • Emergency supply of medicines.
  • Controlled drugs and drug dependence.
  • Adverse reactions to drugs.
  • Guidance on intravenous infusions.
  • Prescribing for children.
  • Prescribing in hepatic impairment.
  • Prescribing in renal impairment.
  • Prescribing in pregnancy.
  • Prescribing in breast-feeding.
  • Prescribing in palliative care.
  • Prescribing for the elderly.
  • Drugs and sport.
  • Prescribing in dental practice.

Notes on Drugs and Preparations

  1. Gastro-intestinal system.
  2. Cardiovascular system.
  3. Respiratory system.
  4. Nervous system.
  5. Infection.
  6. Endocrine system.
  7. Genito-urinary system.
  8. Malignant disease.
  9. Blood and nutrition.
  10. Musculoskeletal system.
  11. Eye.
  12. Ear, nose, and oropharynx.
  13. Skin.
  14. Vaccines.
  15. Anaesthesia.
  16. Emergency treatment of poisoning.

Appendices and Indices

  • Appendix 1 Interactions.
  • Appendix 2 Borderline substances.
  • Appendix 3 Cautionary and advisory labels for dispensed medicines.
  • Appendix 4 Wound management products and elasticated garments.
  • Dental Practitioners’ Formulary.
  • Nurse Prescribers’ Formulary.
  • Non-medical prescribing.
  • Index of proprietary manufacturers.
  • Special-order manufacturers.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/British_National_Formulary >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is a Pharmacopoeia?

Introduction

A pharmacopoeia, pharmacopeia, or pharmacopoea (from the obsolete typography pharmacopœia, meaning “drug-making”), in its modern technical sense, is a book containing directions for the identification of compound medicines, and published by the authority of a government or a medical or pharmaceutical society.

Descriptions of preparations are called monographs. In a broader sense it is a reference work for pharmaceutical drug specifications.

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

Etymology

The term derives from Ancient Greek: φαρμακοποιία pharmakopoiia “making of (healing) medicine, drug-making”, a compound of φάρμακον pharmakon “healing medicine, drug, poison”, the verb ποιεῖν poiein “to make” and the abstract noun suffix -ία -ia.

In early modern editions of Latin texts, the Greek diphthong οι (oi) is latinised to its Latin equivalent oe which is in turn written with the ligature œ, giving the spelling pharmacopœia; in modern UK English, œ is written as oe, giving the spelling pharmacopoeia, while in American English oe becomes e, giving us pharmacopeia.

Brief History

Although older writings exist which deal with herbal medicine, the major initial work in the field is considered to be the Edwin Smith Papyrus in Egypt, Pliny’s pharmacopoeia.

A number of early pharmacopoeia books were written by Persian and Arab physicians. These included The Canon of Medicine of Avicenna in 1025 AD, and works by Ibn Zuhr (Avenzoar) in the 12th century (and printed in 1491), and Ibn Baytar in the 14th century. The Shen-nung pen ts’ao ching (Divine Husbandman’s Materia Medica) is the earliest known Chinese pharmacopoeia. The text describes 365 medicines derived from plants, animals, and minerals; according to legend it was written by the Chinese god Shennong.

Pharmacopeial synopsis were recorded in the Timbuktu manuscripts of Mali.

China

The earliest extant Chinese pharmacopoeia, the Shennong Ben Cao Jing was compiled between 200-250 AD. It contains descriptions of 365 medications.

The earliest known officially sponsored pharmacopoeia was compiled in 659 AD by a team of 23 pharmaceutical scientists led by Su jing during the Tang dynasty (618-907 AD) and was called the Xinxiu Bencao (Newly Revised Canon of Materia Medica). The work consists of 20 volumes with one dedicated to the table of contents, and 25 volumes of pictures with one volume dedicated to the table of contents. A third part consisting of seven volumes contained illustrated descriptions. The text contains descriptions of 850 medicines with 114 new ones. The work was used throughout China for the next 400 years.

City Pharmacopoeia Origins

A dated work appeared in Nuremberg in 1542; a passing student Valerius Cordus showed a collection of medical prescriptions, which he had selected from the writings of the most eminent medical authorities, to the physicians of the town, who urged him to print it for the benefit of the apothecaries, and obtained the sanction of the senatus for his work. A work known as the Antidotarium Florentinum, was published under the authority of the college of medicine of Florence in the 16th century. In 1511, the Concordie Apothecariorum Barchinone was published by the Society of Apothecaries of Barcelona and kept in the School of Pharmacy of the University of Barcelona.

The term Pharmacopoeia first appears as a distinct title in a work published at Basel, Switzerland, in 1561 by A. Foes, but does not appear to have come into general use until the beginning of the 17th century.

Before 1542, the works principally used by apothecaries were the treatises on simples (basic medicinal ingredients) by Avicenna and Serapion; the De synonymis and Quid pro quo of Simon Januensis; the Liber servitoris of Bulchasim Ben Aberazerim, which described preparations made from plants, animals, and minerals, and was the type of the chemical portion of modern pharmacopoeias; and the Antidotarium of Nicolaus de Salerno, containing Galenic formulations arranged alphabetically. Of this last work, there were two editions in use – Nicolaus magnus and Nicolaus parvus: in the latter, several of the compounds described in the large edition were omitted and the formulae given on a smaller scale.

Also Vesalius claimed he had written some “dispensariums” and “manuals” on the works of Galenus. Apparently he burnt them. According to recent research communicated at the congresses of the International Society for the History of Medicine by the scholar Francisco Javier González Echeverría, Michel De Villeneuve (Michael Servetus) also published a pharmacopoeia. De Villeneuve, fellow student of Vesalius and the best galenist of Paris according to Johann Winter von Andernach, published the anonymous ” ”Dispensarium or Enquiridion” in 1543, at Lyon, France, with Jean Frellon as editor. This work contains 224 original recipes by De Villeneuve and others by Lespleigney and Chappuis. As usual when it comes to pharmacopoeias, this work was complementary to a previous Materia Medica that De Villeneuve published that same year. This finding was communicated by the same scholar in the International Society for the History of Medicine, with agreement of John M. Riddle, one of the foremost experts on Materia Medica-Dioscorides works.

Nicolaes Tulp, mayor of Amsterdam and respected surgeon general, gathered all of his doctor and chemist friends together and they wrote the first pharmacopoeia of Amsterdam named Pharmacopoea Amstelredamensis in 1636. This was a combined effort to improve public health after an outbreak of the bubonic plague, and also to limit the number of quack apothecary shops in Amsterdam.

London

Until 1617, such drugs and medicines as were in common use were sold in England by the apothecaries and grocers. In that year the apothecaries obtained a separate charter, and it was enacted that no grocer should keep an apothecary’s shop. The preparation of physicians’ prescriptions was thus confined to the apothecaries, upon whom pressure was brought to bear to make them dispense accurately, by the issue of a pharmacopoeia in May 1618 by the College of Physicians, and by the power which the wardens of the apothecaries received in common with the censors of the College of Physicians of examining the shops of apothecaries within 7 miles of London and destroying all the compounds which they found unfaithfully prepared. This, the first authorized London Pharmacopoeia, was selected chiefly from the works of Mezue and Nicolaus de Salerno, but it was found to be so full of errors that the whole edition was cancelled, and a fresh edition was published in the following December.

At this period the compounds employed in medicine were often heterogeneous mixtures, some of which contained from 20 to 70, or more, ingredients, while a large number of simples were used in consequence of the same substance being supposed to possess different qualities according to the source from which it was derived. Thus crabs’ eyes (i.e. gastroliths), pearls, oyster shells, and coral were supposed to have different properties. Among other ingredients entering into some of these formulae were the excrements of human beings, dogs, mice, geese, and other animals, calculi, human skull, and moss growing on it, blind puppies, earthworms, etc.

Although other editions of the London Pharmacopoeia were issued in 1621, 1632, 1639, and 1677, it was not until the edition of 1721, published under the auspices of Sir Hans Sloane, that any important alterations were made. In this issue many of the remedies previously in use were omitted, although a good number were still retained, such as dogs’ excrement, earthworms, and moss from the human skull; the botanical names of herbal remedies were for the first time added to the official ones; the simple distilled waters were ordered of a uniform strength; sweetened spirits, cordials and ratafias were omitted as well as several compounds no longer used in London, although still in vogue elsewhere. A great improvement was effected in the edition published in 1746, in which only those preparations were retained which had received the approval of the majority of the pharmacopoeia committee; to these was added a list of those drugs only which were supposed to be the most efficacious. An attempt was made to simplify further the older formulae by the rejection of superfluous ingredients.

In the edition published in 1788 the tendency to simplify was carried out to a much greater extent, and the extremely compound medicines which had formed the principal remedies of physicians for 2,000 years were discarded, while a few powerful drugs which had been considered too dangerous to be included in the Pharmacopoeia of 1765 were restored to their previous position. In 1809 the French chemical nomenclature was adopted, and in 1815 a corrected impression of the same was issued. Subsequent editions were published in 1824, 1836, and 1851.

The first Edinburgh Pharmacopoeia was published in 1699 and the last in 1841; the first Dublin Pharmacopoeia in 1807 and the last in 1850.

National Pharmacopoeia Origins

The preparations contained in these three pharmacopoeias were not all uniform in strength, a source of much inconvenience and danger to the public, when powerful preparations such as dilute hydrocyanic acid were ordered in the one country and dispensed according to the national pharmacopoeia in another. As a result, the Medical Act of 1858 ordained that the General Medical Council should publish a book containing a list of medicines and compounds, to be called the British Pharmacopoeia, which would be a substitute throughout Great Britain and Ireland for the separate pharmacopoeias. Hitherto these had been published in Latin. The first British Pharmacopoeia was published in the English language in 1864, but gave such general dissatisfaction both to the medical profession and to chemists and druggists that the General Medical Council brought out a new and amended edition in 1867. This dissatisfaction was probably owing partly to the fact that the majority of the compilers of the work were not engaged in the practice of pharmacy, and therefore competent rather to decide upon the kind of preparations required than upon the method of their manufacture. The necessity for this element in the construction of a pharmacopoeia is now fully recognised in other countries, in most of which pharmaceutical chemists are represented on the committee for the preparation of the legally recognised manuals.

There are national and international pharmacopoeias, like the EU and the US pharmacopoeias. The pharmacopeia in the EU is prepared by a governmental organisation, and has a specified role in law in the EU. In the US, the USP-NF (United States Pharmacopeia – National Formulary) has been issued by a private non-profit organisation since 1820 under the authority of a Convention that meets periodically that is largely constituted by physicians, pharmacists, and other public health professionals, setting standards published in the compendia through various Expert Committees. In the US when there is an applicable USP-NF quality monograph, drugs and drug ingredients must conform to the compendial requirements (such as for strength, quality or purity) or be deemed adulterated or misbranded under the Federal food and drug laws.

Supranational and International Harmonisation

The Soviet Union had a nominally supranational pharmacopoeia, the State Pharmacopoeia of the Union of Soviet Socialist Republics (USSRP), although the de facto nature of the nationality of republics within that state differed from the de jure nature. The European Union has a supranational pharmacopoeia, the European Pharmacopoeia; it has not replaced the national pharmacopoeias of EU member states but rather helps to harmonise them. Attempts have been made by international pharmaceutical and medical conferences to settle a basis on which a globally international pharmacopoeia could be prepared, but regulatory complexity and locoregional variation in conditions of pharmacy are hurdles to fully harmonizing across all countries (that is, defining thousands of details that can all be known to work successfully in all places). Nonetheless, some progress has been made under the banner of the International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), a tri-regional organisation that represents the drug regulatory authorities of the European Union, Japan, and the United States. Representatives from the Pharmacopoeias of these three regions have met twice yearly since 1990 in the Pharmacopoeial Discussion Group to try to work towards “compendial harmonisation”. Specific monographs are proposed, and if accepted, proceed through stages of review and consultation leading to adoption of a common monograph that provides a common set of tests and specifications for a specific material. Not surprisingly, this is a slow process. The World Health Organisation (WHO) has produced the International Pharmacopoeia (Ph.Int.), which does not replace a national pharmacopoeia but rather provides a model or template for one and also can be invoked by legislation within a country to serve as that country’s regulation.

Medical Preparations, Uses, and Dosages

Though formerly printed there has been a transition to a situation where pharmaceutical information is available as printed volumes and on the internet. The rapid increase in knowledge renders necessary frequent new editions, to furnish definite formulae for preparations that have already come into extensive use in medical practice, so as to ensure uniformity of strength, and to give the characters and tests by which their purity and potency may be determined. However each new edition requires several years to carry out numerous experiments for devising suitable formulae, so that current pharmacopoeia are never quite up to date.

This difficulty has hitherto been met by the publication of such non-official formularies as Squire’s Companion to the Pharmacopoeia and Martindale: The complete drug reference (formerly Martindale’s: the extra pharmacopoeia), in which all new remedies and their preparations, uses and doses are recorded, and in the former the varying strengths of the same preparations in the different pharmacopoeias are also compared (Squire’s was incorporated into Martindale in 1952). The need of such works to supplement the Pharmacopoeia is shown by the fact that they are even more largely used than the Pharmacopoeia itself, the first issued in 18 editions and the second in 13 editions at comparatively short intervals. In the UK, the task of elaborating a new Pharmacopoeia is entrusted to a body of a purely medical character, and legally the pharmacist does not, contrary to the practice in other countries, have a voice in the matter. This is notwithstanding the fact that, although the medical practitioner is naturally the best judge of the drug or preparations that will afford the best therapeutic result, they are not as competent as the pharmacist to say how that preparation can be produced in the most effective and satisfactory manner, nor how the purity of drugs can be tested.

The change occurred with the fourth edition of the British Pharmacopoeia in 1898. A committee of the Royal Pharmaceutical Society of Great Britain was appointed at the request of the General Medical Council to advise on pharmaceutical matters. A census of prescriptions was taken to ascertain the relative frequency with which different preparations and drugs were used in prescriptions, and suggestions and criticisms were sought from various medical and pharmaceutical bodies across the British Empire. As regards the purely pharmaceutical part of the work a committee of reference in pharmacy, nominated by the pharmaceutical societies of Great Britain and Ireland (as they were then), was appointed to report to the Pharmacopoeia Committee of the Medical Council.

Some difficulty has arisen since the passing of the Adulteration of Food and Drugs Act concerning the use of the Pharmacopoeia as a legal standard for the drugs and preparations contained in it. The Pharmacopoeia is defined in the preface as only “intended to afford to the members of the medical profession and those engaged in the preparation of medicines throughout the British Empire one uniform standard and guide whereby the nature and composition of, substances to be used in medicine may be ascertained and determined”. It cannot be an encyclopaedia of substances used in medicine, and can be used only as a standard for the substances and preparations contained in it, and for no others. It has been held in the Divisional Courts (Dickins v. Randerson) that the Pharmacopoeia is a standard for official preparations asked for under their pharmacopoeial name. But there are many substances in the Pharmacopoeia which are not only employed in medicine, but have other uses, such as sulphur, gum benzoin, tragacanth, gum arabic, ammonium carbonate, beeswax, oil of turpentine, linseed oil, and for these a commercial standard of purity as distinct from a medicinal one is needed, since the preparations used in medicine should be of the highest possible degree of purity obtainable, and this standard would be too high and too expensive for ordinary purposes. The use of trade synonyms in the Pharmacopoeia, such as saltpetre for purified potassium nitrate, and milk of sulphur for precipitated sulphur, is partly answerable for this difficulty, and has proved to be a mistake, since it affords ground for legal prosecution if a chemist sells a drug of ordinary commercial purity for trade purposes, instead of the purified preparation which is official in the Pharmacopoeia for medicinal use. This would not be the case if the trade synonym were omitted. For many drugs and chemicals not in the Pharmacopoeia there is no standard of purity that can be used under the Adulteration of Food and Drugs Act, and for these, as well as for the commercial quality of those drugs and essential oils which are also in the Pharmacopoeia, a legal standard of commercial purity is much needed. This subject formed the basis of discussion at several meetings of the Pharmaceutical Society, and the results have been embodied in a work called Suggested Standards for Foods and Drugs by C.G. Moor, which indicates the average degree of purity of many drugs and chemicals used in the arts, as well as the highest degree of purity obtainable in commerce of those used in medicine.

An important step has also been taken in this direction by the publication under the authority of the Council of the Pharmaceutical Society of Great Britain of the British Pharmaceutical Codex (BPC), in which the characters of and tests for the purity of many unofficial drugs and preparations are given as well as the character of many glandular preparations and antitoxins that have come into use in medicine, but have not yet been introduced into the Pharmacopoeia. This work may also possibly serve as a standard under the Adulteration of Food and Drugs Act for the purity and strength of drugs not included in the Pharmacopoeia and as a standard for the commercial grade of purity of those in the Pharmacopoeia which are used for non-medical purposes.

Another legal difficulty connected with modern pharmacopoeias is the inclusion in some of them of synthetic chemical remedies, the processes for preparing which have been patented, whilst the substances are sold under trade-mark names. The scientific chemical name is often long and unwieldy, and the physician prefers when writing a prescription to use the shorter name under which it is sold by the patentees. In this case the pharmacist is compelled to use the more expensive patented article, which may lead to complaints from the patient. If the physician were to use the same article under its pharmacopoeial name when the patented article is prescribed, they would become open to prosecution by the patentee for infringement of patent rights. Hence the only solution is for the physician to use the chemical name (which cannot be patented) as given in the Pharmacopoeia, or, for those synthetic remedies not included in the Pharmacopoeia, the scientific and chemical name given in the British Pharmaceutical Codex.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/Pharmacopoeia >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the Pharmacopoeia of the People’s Republic of China?

Introduction

The Pharmacopoeia of the People’s Republic of China (PPRC) or the Chinese Pharmacopoeia (ChP), compiled by the Pharmacopoeia Commission of the Ministry of Health of the People’s Republic of China, is an official compendium of drugs, covering Traditional Chinese and western medicines, which includes information on the standards of purity, description, test, dosage, precaution, storage, and the strength for each drug.

It is recognized by the World Health Organisation (WHO) as the official pharmacopoeia of China.

Content

The ChP, as of its tenth (2015) edition, comes in 4 volumes for both the Chinese and the English versions:

  • Traditional Chinese Medicine, ISBN 978-7-5067-7337-9.
  • Chemical Medicine, ISBN 978-7-5067-7343-0.
  • Biological Preparations, ISBN 978-7-5067-7336-2.
  • General rules and common inactive ingredients, ISBN 978-7-5067-7539-7; new volume.

The English version is collectively coded as ISBN 978-7-5067-8929-5. The 2015 ChP requires Good Manufacturing Practices for all ChP-compliant medications and in general uses INN for English names. The Chinese version arranges medicines in ascending stroke order, while the English translations do so in alphabetical order.

Brief History

The 1997 English version consists of two volumes:

  • Volume 1 (Herbal medicine), 1997, ISBN 7-5025-2062-7.
  • Volume 2 (Western medicine), 1997, ISBN 7-5025-2063-5.

The 1997 Chinese version (in simplified Chinese) also consists of two volumes, but the English and Chinese versions are not direct translations of each other, as they are sorted differently as is in the current edition.

A third volume was added in the 2005 version. The English edition (ISBN 7117069821) describes itself as a “compendium of almost all traditional Chinese medicines and most western medicines and preparations. Information is given for each drug on standards of purity, description, test, dosage, precaution, storage and strength. Key features: A total of 2691 monographs: 992 for traditional Chinese medicines and 1699 for modern western drugs.

“Volume I contains monographs of Chinese material medica and pared slice, vegetable oil/fat and its extract, Chinese traditional patent medicines, single ingredient of Chinese crude drug preparations etc.; Volume II deals with monographs of chemical drugs, antibiotics, biochemical preparations, Radiopharmaceuticals and excipients for pharmaceutical use; Volume III contains biological products.”

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/Pharmacopoeia_of_the_People%27s_Republic_of_China >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the Japanese Pharmacopoeia?

Introduction

The Japanese Pharmacopoeia (日本薬局方) is the official pharmacopoeia of Japan.

Outline

It is published by the Pharmaceuticals and Medical Devices Agency (独立行政法人 医薬品医療機器総合機構, Dokuritsu-gyōsei hōjin iyakuhin-iryō-kiki-sōgō-kikō).

The first edition was published on 25 June 1886, with revisions being issued from time to time. The current revision is number 18, issued electronically on 07 June 2021.

An official English translation is in preparation (status: 06 August 2021).

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/Japanese_Pharmacopoeia >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the Indian Pharmacopoeia Commission?

Introduction

Indian Pharmacopoeia Commission (IPC) is an autonomous institution of the Ministry of Health and Family Welfare which sets standards for all drugs that are manufactured, sold and consumed in India.

Outline

The set of standards are published under the title Indian Pharmacopoeia (IP) which has been modelled on and historically follows from the British Pharmacopoeia. The standards that are in effect since 01 December 2010, are the Indian Pharmacopoeia 2010 (IP 2010). The Pharmacopoeia 2014 was released by Health Minister Ghulam Nabi Azad on 04 November 2013. The Pharmacopoeia 2018 was released by Secretary, Ministry of Health & Family Welfare, Government of India.

IP, the abbreviation of ‘Indian Pharmacopoeia’ is familiar to the consumers in the Indian sub-continent as a mandatory drug name suffix. Drugs manufactured in India have to be labelled with the mandatory non-proprietary drug name with the suffix IP. This is similar to the BP suffix for British Pharmacopoeia and the USP suffix for the United States Pharmacopeia.

The IPC was formed according to the Indian Drugs and Cosmetics Act of 1940 and established by executive orders of the Government of India in 1956.

History of Publication

The actual process of publishing the first Pharmacopoeia started in the year 1944 under the chairmanship of Colonel R.N. Chopra. The IP list was first published in the year 1946 and was put forth for approval. The titles are suffixed with the respective years of publication, e.g. IP 1996. The following table describes the publication history of the Indian Pharmacopoeia.

  • 1st Edition 1955:
    • Supplement 1960
  • 2nd Edition 1966:
    • Supplement 1975
  • 3rd Edition 1985:
    • 2 volumes.
    • Addendum 1989.
    • Addendum 1991.
  • 4th Edition 1996:
    • 2 volumes.
    • Addendum 2000.
    • Vet Supplement 2000.
    • Addendum 2002.
    • Addendum 2005.
  • 5th Edition 2007:
    • 3 volumes.
    • Addendum 2008.
  • 6th Edition 2010:
    • 3 volumes.
    • Addendum 2012.
  • 7th Edition 2014:
    • 4 volumes.
    • Addendum 2015.
    • Addendum 2016.
  • 8th Edition 2018:
    • 4 volumes.
    • Addendum 2019.
    • Addendum 2021.

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/Indian_Pharmacopoeia_Commission >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the United States Pharmacopoeia?

Introduction

The United States Pharmacopeia (USP) is a pharmacopeia (compendium of drug information) for the United States published annually by the United States Pharmacopeial Convention (usually also called the USP), a non-profit organisation that owns the trademark and also owns the copyright on the pharmacopeia itself.

The USP is published in a combined volume with the National Formulary (a formulary) as the USP-NF. If a drug ingredient or drug product has an applicable USP quality standard (in the form of a USP-NF monograph), it must conform in order to use the designation “USP” or “NF”. Drugs subject to USP standards include both human drugs (prescription, over-the-counter, or otherwise) and animal drugs. USP-NF standards also have a role in US federal law; a drug or drug ingredient with a name recognized in USP-NF is considered adulterated if it does not satisfy compendial standards for strength, quality or purity. USP also sets standards for dietary supplements and food ingredients (as part of the Food Chemicals Codex). USP has no role in enforcing its standards; enforcement is the responsibility of the US Food and Drug Administration (FDA) and other government authorities in the United States.

Product Quality: Standards and Verification

USP establishes written (documentary) and physical (reference) standards for medicines, food ingredients, dietary supplement products, and ingredients. These standards are used by regulatory agencies and manufacturers to help to ensure that these products are of the appropriate identity, as well as strength, quality, purity, and consistency. USP 800 is an example of a publication created by the United States Pharmacopeia.

Prescription and over-the-counter medicines available in the United States must, by federal law, meet USP-NF public standards, where such standards exist. Many other countries use the USP-NF instead of issuing their own pharmacopeia, or to supplement their government pharmacopeia.

USP’s standards for food ingredients can be found in its Food Chemicals Codex (FCC). The FCC is a compendium of standards used internationally for the quality and purity of food ingredients like preservatives, flavourings, colourings and nutrients. While the FCC is recognised in law in countries like Australia, Canada and New Zealand, it currently does not have statutory recognition in the United States, although FCC standards are incorporated by reference in over 200 FDA food regulations. USP obtained the FCC from the Institute of Medicine in 2006. The IOM had published the first five editions of the FCC.

USP also conducts verification programs for dietary supplement products and ingredients. These are testing and audit programmes. Products that meet the requirements of the programme can display the USP Verified Dietary Supplement Mark on their labels. This is different from seeing the letters “USP” alone on a dietary supplement label, which means that the manufacturer is claiming to adhere to USP standards. USP does not test such products as it does with USP Verified products.

Healthcare Information

In the past, Congress authorised the Secretary of HHS to request USP to develop a drug classification system that Medicare Prescription Drug Benefit plans may use to develop their formularies, and to revise such classification from time to time to reflect changes in therapeutic uses covered by Part D drugs and the addition of new covered Part D drugs. USP has developed six versions of the Model Guidelines, the last issued early in 2014 for the 2015-2017 benefit years.

Promoting the Quality of Medicines Programme

Since 1992, USP has worked cooperatively with the United States Agency for International Development (USAID) to help developing countries address critical issues related to poor quality medicines. This partnership operated as the Drug Quality and Information (DQI) programme until 2009, when, to better meet growing global needs, USAID awarded USP a five-year, $35 million cooperative agreement to establish a new, expanded programme: Promoting the Quality of Medicines (PQM). In 2013 USAID extended the PQM programme for five years (through September 2019), increased its funding to $110 million, and expanded the geographical reach of the programme.

PQM serves as a primary mechanism to help USAID-supported countries strengthen their quality assurance and quality control systems to better ensure the quality of medicines that reach patients. PQM has four key objectives:[9]

  • Strengthen quality assurance (QA) and quality control (QC) systems.
  • Increase the supply of quality assured medicines.
  • Combat the availability of substandard and counterfeit medicines.
  • Provide technical leadership and global advocacy.

USP-USAID collaborative efforts have helped communities improve drug quality in more than 35 countries. PQM currently works in Africa, Asia, Europe/Eurasia, and the Caribbean/Latin America.

International Agreements and Offices

USP works internationally, largely through agreements with other pharmacopeias, as well as regulatory bodies, manufacturer associations and others. In recent years, USP signed a series of Memoranda of Understanding (MOU) with groups including the Pharmacopeia of the People’s Republic of China Chinese Pharmacopeia Commission, nine countries belonging to the Association of Southeast Asian Nations (ASEAN), and the Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (Roszdravnadzor). USP also operates an international office in Switzerland and offices and laboratories in Brazil, India, and China.

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/United_States_Pharmacopeia >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the European Pharmacopoeia?

Introduction

The European Pharmacopoeia (Pharmacopoeia Europaea, Ph. Eur.) is a major regional pharmacopoeia which provides common quality standards throughout the pharmaceutical industry in Europe to control the quality of medicines, and the substances used to manufacture them. It is a published collection of monographs which describe both the individual and general quality standards for ingredients, dosage forms, and methods of analysis for medicines. These standards apply to medicines for both human and veterinary use.

Legal Basis

The European Pharmacopoeia has a legally binding character. It is used as an official reference to serve public health, and is part of the regulatory requirements for obtaining a Marketing Authorisation (MA) for a medicinal (human or veterinary) product. The quality standards of the European Pharmacopoeia apply throughout the entire life-cycle of a product, and become legally binding and mandatory on the same date in all thirty-nine (39) signatory states, which include all European Union member states.

Several legal texts make the European Pharmacopoeia mandatory in Europe. The Convention on the Elaboration of a European Pharmacopoeia (ETS No. 50) which was adopted by the Council of Europe in 1964, laid the groundwork for the development of the European Pharmacopoeia. In 1994, a Protocol (ETS No. 134) was adopted, amending the convention to prepare for the accession of the European Union (EU), and defining the respective powers of the European Union and its member states within the European Pharmacopoeia Commission.

European Union Directive 2001/82/EC and Directive 2001/83/EC, (as amended) state the legally binding character of European Pharmacopoeia texts for Marketing Authorisation Applications (MAA). All manufacturers of medicines or substances for pharmaceutical use therefore must apply the European Pharmacopoeia quality standards in order to be able to market and use these products in Europe.

As of February 2020, thirty-nine (39) member states and the European Union are signatories to the Convention on the Elaboration of a European Pharmacopoeia. There are 30 observers in all: five European countries, 23 non-European countries, the World Health Organisation (WHO) and the Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare.

The European Pharmacopoeia Commission

While the European Directorate for the Quality of Medicines & HealthCare (EDQM), a directorate of the Council of Europe, provides scientific and administrative support for the European Pharmacopoeia, the governing body is the European Pharmacopoeia Commission. The European Pharmacopoeia Commission determines the general principles applicable to the elaboration of the European Pharmacopoeia. It also decides the work programme, sets up and appoints experts to the specialised groups responsible for preparing monographs, adopts these monographs, and recommends dates for the implementation of its decisions within the territories of the contracting parties.

This Commission meets in Strasbourg, France, three times a year, to adopt texts proposed by its groups of experts, and to decide on its programme of work and general policies. Items are added to the work programme in response to requests received by the European Directorate for the Quality of Medicines & HealthCare from the member states and their national authorities, industry or experts from around the world, based on current scientific and health issues. Each national delegation has one vote. In all technical questions, the decisions of the commission are taken by a unanimous vote of the national delegations that cast a vote. Member states’ representatives mostly come from health authorities, national pharmacopoeia authorities and universities; and are appointed by the national authorities on the basis of their expertise. Representatives of the thirty (30) observers are invited to attend the sessions, but cannot vote.

The term of the chair of the commission is three years, and runs in parallel with other members of the commission’s Presidium.

Publication

The first edition of the European Pharmacopoeia was published in 1969, and consisted of 120 texts. The 10th edition, currently applicable, was published in July 2019. The Ph. Eur. is applicable in 39 European countries and used in over 100 countries worldwide. Nowadays it contains over 3000 texts (the monographs), covering all therapeutic areas and consisting of:

  • Individual texts describing legally-binding quality standards for substances used in the manufacture of medicines or medicine ingredients (including active pharmaceutical ingredients, excipients, herbals, etc.);
  • Individual texts describing legally-binding quality standards for finished products;
  • General monographs describing legally-binding quality standards for classes of substances (such as fermentation products or substances for pharmaceutical use) or for the dosage forms that medicines can take (tablets, capsules, injections, etc.); and
  • General methods of analysis of substances used in the manufacture of medicines, which are not legally binding and may also be used for substances and medicines not described in the Ph. Eur.

Ph. Eur. texts contain detailed analytical methods to identify the substance or product and control its quality and quantitative strength.

Ph. Eur. texts also address the issue of impurities in medicinal products, which do not offer any therapeutic benefit for the patient and sometimes are potentially toxic. Impurities are present at every stage of the manufacture of medicines: in starting materials, active pharmaceutical ingredients (APIs), reagents, intermediates, excipients and primary packaging materials. But Ph. Eur. texts’ section on impurities is perhaps the most essential part of a quality standard of an active substance.

A new edition of the European Pharmacopoeia is published every three years: in both English and French, by the Council of Europe. It is made available in print and electronic (online and downloadable) versions; the online version is also accessible from smartphones and tablet computers.

Translations into other languages are published by the member states themselves. For example, a German version is jointly published by Austria, Germany and Switzerland.

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/European_Pharmacopoeia >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.

What is the International Pharmacopoeia?

Introduction

The International Pharmacopoeia (Pharmacopoeia Internationalis, Ph. Int.) is a pharmacopoeia issued by the World Health Organisation (WHO) as a recommendation, with the aim to provide international quality specifications for pharmaceutical substances (active ingredients and excipients) and dosage forms, together with supporting general methods of analysis, for global use. Its texts can be used or adapted by any WHO member state wishing to establish legal pharmaceutical requirements.

The Ph.Int. is based primarily on medicines included in the current WHO Model List of Essential Medicines (EML) and medicines included in the current invitations to manufacturers to submit an expression of interest (EOI) to the WHO Prequalification Team – Medicines (PQT) and those of interest to other UN organisations. In recent years, priority has been given to medicines of importance in low and middle income countries, which may not appear in any other pharmacopoeias, including child-friendly dosage forms.

The Ph.Int. is designed to serve all Member States, especially their national and regional regulatory authorities, organisations in the United Nations system, and regional and interregional harmonisation efforts, and they underpin important public health initiatives, including the prequalification and procurement of quality medicines through major international entities, such as the Global Fund to Fight AIDS, Tuberculosis and Malaria, and UNICEF.

The monographs published in the Ph.Int. are established in an independent manner via a consultative procedure and based on international experience. Monographs on radiopharmaceuticals developed with the International Atomic Energy Agency.

Refer to The International Pharmacopoeia, British Pharmacopoeia, European Pharmacopoeia, United States Pharmacopoeia, Indian Pharmacopoeia Commission, Japanese Pharmacopoeia, and Pharmacopoeia of the People’s Republic of China.

This page is based on the copyrighted Wikipedia article < https://en.wikipedia.org/wiki/The_International_Pharmacopoeia >; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA.